Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1966 to 1980 of 9006 results

  1. Pembrolizumab for treating advanced or recurrent endometrial cancer with mismatch repair deficiency [ID6710]

    Awaiting development Reference number: GID-TA11931 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]

    In development Reference number: GID-TA10905 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Shared decision-making: practical guidance for health and social care professionals

    Awaiting development Reference number: GID-QS10097 Expected publication date: TBC

    Quality standard
    Awaiting development

  4. Advocacy services for adults with health and social care needs

    Awaiting development Reference number: GID-QS10145 Expected publication date: TBC

    Quality standard
    Awaiting development

  5. Safeguarding adults in care homes

    Awaiting development Reference number: GID-QS10147 Expected publication date: TBC

    Quality standard
    Awaiting development

  6. Supporting independent living and preventing isolation in adults of working age with social care needs

    Awaiting development Reference number: GID-QS10149 Expected publication date: TBC

    Quality standard
    Awaiting development

  7. Pernicious anaemia

    Awaiting development Reference number: GID-QS10130 Expected publication date: TBC

    Quality standard
    Awaiting development

  8. Domestic Abuse

    In development Reference number: GID-NG10449 Expected publication date:  08 October 2027

    NICE guideline
    In development

  9. School-based interventions: physical and mental health and wellbeing promotion

    In development Reference number: GID-QS10070 Expected publication date: TBC

    Quality standard
    In development

  10. Managing symptoms with an uncertain cause

    Awaiting development Reference number: GID-QS10103 Expected publication date: TBC

    Quality standard
    Awaiting development

  11. Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawal

    Awaiting development Reference number: GID-QS10106 Expected publication date: TBC

    Quality standard
    Awaiting development

  12. Middle meningeal artery embolisation for chronic subdural haematomas

    In development Reference number: GID-IPG10440 Expected publication date:  19 November 2026

    Interventional procedures guidance
    In development

  13. Teprotumumab for treating thyroid eye disease (deferred appraisal of D1) [ID6756]

    In development Reference number: GID-TA11995 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Tarlatamab for treating extensive stage small-cell lung cancer that has progressed after platinum-based chemotherapy [ID6617]

    In development Reference number: GID-TA11812 Expected publication date:  13 January 2027

    Technology appraisal guidance
    In development

  15. Decitabine–cedazuridine with venetoclax for untreated acute myeloid leukaemia when intensive induction chemotherapy is unsuitable [ID6601]

    In development Reference number: GID-TA11765 Expected publication date:  24 March 2027

    Technology appraisal guidance
    In development